Aescap Life Sciences & Aescap Genetics Fund
Investing in the future winners of biotech
The Aescap Life Sciences Fund and Aescap Genetics fund invest in companies that are developing tomorrow’s medicines. Thereby we provide investors the chance to invest into the future winners of the biotech industry.
Both funds aim for capital growth and an average net return (net of expenses) of at least 20% annually over the medium term (4-5 years). To maximize returns and mitigate risk, we diversify our portfolios over many disease areas, different phases of company development and geographical areas.
Our Portfolio Manager has over 30 years of experience investing in the biotech/life sciences market and the Investment Team consists of experienced professionals with different backgrounds in investing and the healthcare industry.
An investment in our funds will not only allow for a good return on investment. It also enables the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others.